GlassScriptPhysician profile
Dawn P Hrab
NPI 1003870056
$1,244.71
in general payments reported to CMS, 2019-2025
24 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $141 · 2020: $40.79 · 2021: $210 · 2022: $433 · 2023: $420.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $420.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $420.09 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $198.86 | 2019-2023 | Trulicity, Mounjaro, Jardiance |
| Glaxosmithkline, LLC. | $182.18 | 2019-2023 | Trelegy Ellipta, Shingrix, Bexsero |
| Abbvie INC. | $168.95 | 2021-2023 | |
| Baxter Healthcare | $116.85 | 2023 | Hillrom - Cardiac Ambulatory Monitor |
| Merck Sharp & Dohme LLC | $86.87 | 2019-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $67.88 | 2021-2023 | Stiolto Respimat |
| Novo Nordisk INC | $57.28 | 2020-2022 | |
| Sanofi Pasteur INC. | $45.63 | 2020-2023 | |
| Paratek Pharmaceuticals, INC. | $40.27 | 2022-2023 | Nuzyra |
| Takeda Pharmaceuticals U.S.A., INC. | $34.30 | 2022 | |
| Hikma Pharmaceuticals USA | $26.37 | 2023 | Ryaltris |
| Daiichi Sankyo INC. | $23.60 | 2022 | |
| Lundbeck LLC | $21.68 | 2022 | |
| Janssen Pharmaceuticals, INC | $20.27 | 2019 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $18.29 | 2022 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kowa Pharmaceuticals America, INC. | $17.52 | 2019 | |
| Teva Pharmaceuticals USA, INC. | $17.35 | 2022 | |
| Exact Sciences Corporation | $17.34 | 2023 | Cologuard Collection Kit |
| Astellas Pharma US INC | $14.94 | 2023 | Veozah |
| Bayer Healthcare Pharmaceuticals INC. | $14.44 | 2021 | |
| Jazz Pharmaceuticals INC. | $14.30 | 2022 | |
| Amarin Pharma, INC. | $13.88 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $13.24 | 2019 | |
| Novartis Pharmaceuticals Corporation | $12.42 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Dawn Hrab listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.